Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Discovering the anticancer mechanism of 52-deoxy-52- methylthioadenosine in cholangiocarcinoma cells using quantitative proteomics analysis

ABSTRACT: Cholangiocarcinoma (CCA) is a highly aggressive cancer originating from the bile duct epithelium. It has been on the rise globally, especially in Asian countries where the liver ûuke infection is prevalent. Current chemotherapy treatments for CCA are often ineûective due to drug resistance. Thus, there is a pressing need for new, eûective anticancer agents. This study explores the potential of 5'-deoxy-5'-methylthioadenosine (MTA), a naturally occurring nucleoside, in treating CCA. MTA has shown promise in inhibiting cell proliferation and invasion in various cancer types, but its eûects on CCA have not been studied.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Sumalee Obchoei

PROVIDER: PXD049119 | JPOST Repository | Wed May 15 00:00:00 BST 2024

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	KKU-213MTA-1_1.mzXML	Mzxml
	KKU-213MTA-1_1_BB3_01_2829.mgf	Mgf
	KKU-213MTA-1_2.mzXML	Mzxml
	KKU-213MTA-1_2_BB3_01_2830.mgf	Mgf
	KKU-213MTA-1_3.mzXML	Mzxml

Items per page:

1 - 5 of 20

Similar Datasets

Serum exosome miRNA expression profile in patients with cholangiocarcinoma(CCA) and common bile duct stones(CBDS)

Project description:Cholangiocarcinoma (CCA) is a type of highly aggressive cancer arising from the biliary system. Through serum exosome miRNA sequencing, we screened out the differentially expressed miRNA in patients with cholangiocarcinoma(CCA) and common bile duct stones(CBDS).

2022-10-20 | GSE215448 | GEO

New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.

Project description:Cholangiocarcinoma (CCA) is a deadly tumour lacking effective therapies. Clinically-relevant experimental models and analysis of human samples represent the cornerstone of mechanistic cancer research. Thioacetamide (TAA)-induced intrahepatic CCA (iCCA) in rats encompasses key histological and molecular features of human iCCA. Molecular studies in bile may capture carcinogenic alterations and therapeutic vulnerabilities in CCA. We performed bile proteomic and metabolomic analyses in this model leading us to identify unrecognized mechanisms relevant to human iCCA.

2022-06-09 | PXD032802 | Pride

Identification of RNF213 as a potential suppressor of local invasion in intrahepatic cholangiocarcinoma

Project description:Intrahepatic cholangiocarcinoma (ICC) is a lethal cancer arising from intrahepatic bile ducts in the liver. In the intraductal growth (IDG) type, also referred to as intraductal papillary neoplasm of the bile duct (IPNB), a rare subtype of ICC, cancer cells originating within the bile duct usually invade and infiltrate the nearby liver tissues, resulting in local invasion. IPNB can serve as a good disease model to study the mechanism of local invasion, which is the earliest step of metastasis. Here, we aimed to identify the genes associated with local invasion by comparing the somatic mutations of the matched IPNB tissues with and without local invasion from a set of 11 patients using the Ion AmpliSeq Comprehensive Cancer Panel. Somatic mutation profiling analysis identified RNF213 as a potential candidate gene associated with local invasion in ICC patients. We established stable RNF213-knockdown and shControl cholangiocarcinoma (CCA) cell lines (HuCCT1, YSCCC, and KKU-100). Next, the expression profiling of the RNF213-knockdown and shContol CCA cell lines was analyzed by RNA sequencing.

2024-07-24 | GSE235891 | GEO

Biomarkers of Cholangiocarcinoma and Pancreatic adenocarcinoma

Project description:Cholangiocarcinoma (CCA) and pancreatic adenocarcinoma (PDAC) may lead to the development of extrahepatic obstructive cholestasis. However, biliary stenoses can also be caused by benign conditions, and the identification of their etiology still remains a clinical challenge. We performed metabolomic and proteomic analyses of bile from patients with benign (n=36) and malignant conditions, CCA (n=36) or PDAC (n=57), undergoing endoscopic retrograde cholangiopancreatography with the aim of characterizing bile composition in biliopancreatic disease and identifying biomarkers for the differential diagnosis of biliary strictures. Comprehensive analyses of lipids, bile acids and small molecules were carried out using mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (1H-NMR) in all patients. MS analysis of bile proteome was performed in five patients per group. We implemented artificial intelligence tools for the selection of biomarkers and algorithms with predictive capacity. Our machine-learning pipeline included the generation of synthetic data with properties of real data, the selection of potential biomarkers (metabolites or proteins) and their analysis with neural networks (NN). Selected biomarkers were then validated with real data. We identified panels of lipids (n=10) and proteins (n=5) that when analyzed with NN algorithms discriminated between patients with and without cancer with an unprecedented accuracy.

2021-09-09 | PXD019924 | Pride

Patient-derived model combining organoids and matrix reveals cholangiocarcinoma promoting properties of the microenvironment

Project description:Cholangiocarcinoma (CCA) is a rare but aggressive type of primary liver cancer, with an overall 5-year survival rate of <10%. The extracellular matrix (ECM) plays a particularly important role in CCA tumor biology, manifested in the desmoplastic tumor environment. This study aim is to design an in vitro CCA model combining patient-derived cells and patient-derived ECM mimicking the native microenvironment. decellularized Patient CCA tissue (CCA-matrix; CCA-M) and tumor-free liver tissue (TFL-M) was decellularized and repopulated with CCA organoids (CCAOs). Culture was performed with amino acids labeled with stable heavy isotopes to enable separation of pre-existing ECM from proteins produced by the cells in the mass spectrometry (MS) analysis. CCAOs on decellularized matrix form complex morphological structures, with environment-dependent proliferation and migration dynamics, driven by the occurrence of EMT. CCAOs in TFL-M or CCA-M can be used to study the initiation or progression of desmoplasia in CCA, respectively. Furthermore, in-depth transcriptomic and proteomic analysis reveals that CCA-M induces a transcriptome more resembling in vivo CCA tumor tissue, with an accompanying protective effect of the desmoplastic environment on tumor survival.

2023-03-04 | PXD028408 | Pride

A novel 3-D organotypic culture model by co-culturing alpha-SMA positive CAF and cholangiocarcinoma cells in a collagen matrix

Project description:The increased M-NM-1-smooth muscle-actin positive cancer-associated fibroblastic cells (CAF) in the desmoplastic stroma may relate to a more aggressive cancer and worse survival outcomes for intrahepatic cholangiocarcinoma (ICC) patients We developed a novel 3-D organotypic culture model by co-culturing M-NM-1-SMA positive CAF and cholangiocarcinoma cells in a collagen matrix. Cholangiocarcinoma cell lines were established by isolating M-NM-1-SMA positive cancer-associated fibroblastic cells (CAF) (BDEsp-TDFE4) and cholangiocarcinoma cells (BDEsp-TDEH10) from tumors arising from bile duct inoculation of spontaneously-transformed low grade malignant rat BDE1 cholangiocytes (BDEsp cells). These tumor-derived cells lines were then grown in a rat tail type I collagen gel matrix, alone or in co-culture, and their gene expression profile were compared.

2012-06-22 | E-GEOD-38889 | biostudies-arrayexpress

Proteomic analysis of distal cholangiocarcinoma

Project description:Distal cholangiocarcinoma is an aggressive malignancy with a dismal prognosis. There is a lack of diagnostic and prognostic biomarkers. An improved understanding of proteomic changes associated with malignancy and identification of potential biomarkers can help improve the survival of patients. A workflow utilizing discovery mass spectrometry and verification by parallel-reaction monitoring was used to analyze surgically resected formalin-fixed paraffin embedded samples from distal cholangiocarcinoma patients and normal bile ducts in order to identify differentially expressed proteins. 20 tumors and 6 controls were successfully analyzed in the discovery experiment and 16 tumors and 9 controls in the PRM analysis. In the discovery experiment a total of 3057 proteins were identified. 87 proteins were found to be differentially expressed between the conditions (q<0.05 and fold change ≥2 or ≤0.5). 31 proteins were upregulated in the distal cholangiocarcinoma samples as compared to controls and 56 downregulated. Bioinformatic analysis revealed an abundance of the differentially expressed proteins to be associated with the tumor reactive stroma. Parallel-reaction monitoring verified 28 proteins as upregulated and 18 as downregulated. In conclusion several proteins without prior association with cholangiocarcinoma biology were identified and verified as differentially expressed between distal cholangiocarcinoma samples and normal bile ducts. These proteins can be further evaluated to elucidate their biomarker potential and role in distal cholangiocarcinoma carcinogenesis.

2020-09-09 | PXD017906 | Pride

MBD2 regulates the progression and chemoresistance of cholangiocarcinoma through interaction with WDR5

Project description:Background: Cholangiocarcinoma (CCA) is a high malignancy, rapid progression tumor of bile duct. Due to its chemoresistance, it always has an extremely poor prognosis. Therefore, it is still need to detailed elucidation the mechanisms of chemoresistance and find the therapeutic targets. Methods: We analysis the expression of MBD2 in CCA and normal bile duct tissues through public database and immunohistochemical (IHC). The role of MBD2 in CCA cells’ proliferation, migration, chemoresistance ability was validated through CCK-8, plate clone assay, wound healing assay, xenograft mice models. Besides, we construct a primary CCA mice model to further confirm the effect of MBD2. RNA-seq, co-IP-MS were used to find the mechanisms of MBD2 leading to chemoresistance. Results: MBD2 is up-regulated in CCA. It could promote the proliferation, migration and chemoresistance of CCA cells. Mechanistically, MBD2 could directly interact with WDR5, and binding to the promoter of ABCB1, then promote the tri-methylation of H3K4 in this region through KMT2A, active the expression of ABCB1. Knocking down of WDR5 or KMT2A could block the transcriptional activation of ABCB1 by MBD2. MM-102 is a molecular inhibitor that targets the interaction of WDR5 with KMT2A. MM-102 could inhibit the expression of ABCB1 in CCA cells, and decrease the chemoresistance of CCA to cisplatin. Conclusion: MBD2 promote the progress and chemoresistance of CCA through interact with WDR5. MM-102 could effectively block this procedure and enhance the sensitivity to cisplatin of CCA.

2024-09-30 | GSE275477 | GEO

Human cholangiocarcinoma LC-MS/MS

Project description:The glycosylation landscape of Human cholangiocarcinoma (CCA), and how it affects CCA diagnosis and prognosis, has recently emerged as an appealing research field.In this study, we used chemical glycoproteomic analysis Click-iG for systematic profiling of intact glycopeptides in CCA and HIBEpiC cell lines.

2024-06-22 | PXD048188 | Pride

Cholangiocarcinoma tissues VS. corresponding normal bile duct tissues

Project description:To identify miRNAs differentially expressed in cholangiocarcinoma,3 human cholangiocarcinoma and their corresponding normal bile duct tissues were obtained from 3 patients after operation with postoperative pathological diagnosed perihilar or distal biliary cholangiocarcinoma miRNAs expression in human cholangiocarcinoma/normal bile duct samples was measured after operation.Three independent experiments were performed using different patients for each experiment.

2013-06-10 | E-GEOD-47764 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data